Nrf2 Polypeptide Delivery for Ocular Oxidative Stress
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for oxidative stress-related diseases such as diabetic retinopathy and age-related macular degeneration are inadequate in effectively reducing oxidative stress and inflammation in the eye, leading to tissue damage and vision loss.
Innovation Solution
A recombinant polypeptide comprising a cell-penetrating peptide, an Nrf2 peptide, and a secretion signal is delivered using a viral vector, such as AAV, to induce antioxidant gene expression and reduce inflammatory markers like IL-1β, thereby mitigating oxidative stress and inflammation in ocular tissues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for oxidative stress-related diseases, then disease management is maintained, but oxidative stress and inflammation in ocular tissues are not effectively reduced, leading to tissue damage and vision loss
Solution Approach 1:
The patent uses Nrf2 peptide as an intermediary molecule that activates the endogenous antioxidant defense system. The Nrf2 peptide binds to Keap-1, releasing Nrf2 to translocate to the nucleus and activate antioxidant response elements, thereby indirectly combating oxidative stress without directly introducing antioxidant compounds
Solution Approach 2:
The invention enables the cell's own antioxidant defense system to combat oxidative stress by activating the Nrf2-Keap-1 pathway. Instead of providing external antioxidants, the treatment stimulates the body's intrinsic protective mechanisms to produce endogenous antioxidants, making the system self-service and self-regulating
2Productivity
If a viral vector is used to deliver the recombinant polypeptide, then delivery efficiency to ocular tissues is improved, but potential immunogenicity and inflammation are introduced
Solution Approach 1:
The patent modifies the viral vector parameters by using replication-defective designs and optimizing transduction efficiency to achieve effective gene delivery while minimizing immunogenic responses. The AAV vector parameters are adjusted to balance delivery efficacy with reduced inflammatory potential
Solution Approach 2:
The secretion signal sequence acts as an intermediary element that facilitates the release of the Nrf2 peptide from the viral vector into the extracellular space, enabling paracrine signaling to neighboring cells while reducing the immunogenic load associated with viral vector presence
3Reliability
If the recombinant polypeptide is designed with multiple components (secretion signal, carrier protein, cell penetrating peptide, Nrf2 peptide), then cellular uptake and activity are enhanced, but device complexity increases
Solution Approach 1:
The patent merges multiple functional elements (secretion signal, carrier protein, cell penetrating peptide, and Nrf2 peptide) into a single recombinant polypeptide construct. This consolidation ensures coordinated delivery, cellular uptake, and biological activity while simplifying production and dosing compared to administering separate components
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The delivery of the recombinant polypeptide significantly increases antioxidant enzyme expression, reduces oxidative protein modifications, enhances cell viability, and decreases inflammatory responses in ocular tissues, providing therapeutic benefits for oxidative stress-related eye diseases.
Implementation Method 1
a cell penetrating peptide
Implementation Method 2
induce antioxidant gene expression
Implementation Method 3
reduces oxidative protein modifications
Implementation Method 4
reduces secretion of IL-1β
Data Source
AI summary
The present invention provides methods and compositions for treating and/or preventing age related macular degeneration and other conditions involving macular degeneration, ocular neovascularization, or inflammation, including ocular inflammation. In some embodiments, the methods comprise administering an expression vector that delivers a secretable and cell penetrating Nrf2 to a subject in need thereof.